Report
EUR 89.58
For Business Accounts Only
While the majority of the Chapter 18A IPOs has a focus on innovative oncology drugs, this company is unique in the sense that it has a long list of ophthalmology drugs in the late stage of development. The company's assets cover major eye diseases (cataracts, glaucoma, age-related macular degeneration (AMD), dry eye syndrome and allergic conjunctivitis) except diabetic retinopathy (DR).
Looking at its product pipeline, we had an impression that the company's key assets are mainly licensed in products which have not proven to generate big revenue in the overseas market though there is improvement over the current standard of care.
Despite a short history of operation, the company has a broad spectrum of ophthalmological indications and is backed by reputable investors. The management is experienced and has track record of drug development in the relevant field.
Ocumension (欧康维视) Pre-IPO - All ready for a great listing except a block buster
Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic therapies, aims to raise up to USD 300 million via a Hong Kong listing.While the majority of the Chapter 18A IPOs has a focus on innovative oncology drugs, this company is unique in the sense that it has a long list of ophthalmology drugs in the late stage of development. The company's assets cover major eye diseases (cataracts, glaucoma, age-related macular degeneration (AMD), dry eye syndrome and allergic conjunctivitis) except diabetic retinopathy (DR).
Looking at its product pipeline, we had an impression that the company's key assets are mainly licensed in products which have not proven to generate big revenue in the overseas market though there is improvement over the current standard of care.
Despite a short history of operation, the company has a broad spectrum of ophthalmological indications and is backed by reputable investors. The management is experienced and has track record of drug development in the relevant field.
Underlying
Ocumension Therapeutics
Provider
Aequitas Research
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Ke Yan
Other Reports on these Companies
Other Reports from Aequitas Research
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.